2025-09-25T14:15:26Z 2024-12-31 990 2024-01-01 271652696 INTERNATIONAL THYMIC MALIGNANCY INTEREST GROUP INTE 6092148616 102 Legend Drive Sleepy Hollow NY 10591 Alan Neibauer Co-director 6092148616 2025-08-28 2024 2025-03-06 01:10:19Z X Pamela Bruce 102 Legend Drive Unit 102 Sleepy Hollow NY 10591 373790 false X Www.itmig.org X 2010 DE The mission of ITMIG is to promote the advancement of clinical and basic science pertaining to thymic and other mediastinal malignancies and related conditions ITMIG is a multidisciplinary group currently consisting of surgeons, pathologists, imaging specialists, oncologists, and neurologists, aiming for better management of patients with thymic tumors through an optimized interaction between the disciplines. The academic journal Mediastinum has become the official journal of the International Thymic Malignancy Interest Group! This represents a collaborative partnership between two institutions. The ITMIG database is a major resource for studying the characteristics, treatment strategies, and outcomes of patients with thymic malignancies, has reopened More than 2000 patients are enrolled. The Biology Working Group has been created, . 4 4 0 0 0 164486 373790 0 0 0 164486 373790 138896 0 0 0 0 0 229580 138896 229580 25590 144210 167923 312142 0 0 167923 312142 X The mission of ITMIG is to promote the advancement of clinical and basic science pertaining to thymic and other mediastinal malignancies and related conditions false false 80000 ITMIG is aligned with the Foundation for Thymic Cancer Research to advance program services through coordination of the executive director. 64399 The ITMIG database is a major resource for studying the characteristics, treatment strategies, and outcomes of patients with thymic malignancies. More than 2000 patients are enrolled. The database is open to all researches and has data transfer agreements with all major institutions. 30000 The 2024 Annual Meeting was held in Yokohama, Japan, in collaboration with the Japan Lung Cancer Society. The abstract book from the meeting is available in MEDIASTINUM. 36181 210580 true true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true 0 0 0 false false false false false false false false false false false false false false false false false false false false false X 4 4 false false false false false false false false false false false false true false false false false false false false false X Pam Bruce 6092148616 102 Legend Drive Unit 102 Sleepy Hollow NY 10591 Pam Bruce Director 40.00 0.00 X 0 0 0 Dr Malgorzata Szolkowska President 25.00 0.00 X 0 0 0 Dr Paolo Mendogni Secretary 25.00 X 0 0 0 Dr Annemarie Fernandes Shepherd Treasurer 25.00 X 0 0 0 Dr Dirk Van Raemdonck Vjce President 25.00 X 0 0 0 0 0 0 0 false false false 0 373790 373790 373790 0 0 0 19000 19000 0 0 210580 210580 229580 210580 19000 0 167923 312142 167923 312142 0 0 X 167923 312142 0 0 0 0 0 0 167923 312142 167923 312142 144210 X false false false X 0 63603 181356 106832 164486 377806 894083 63603 181356 106832 164486 377806 894083 0 0 0 894083 0 0 0 0 0 0 0 0 0 0 63603 181356 106832 164486 377806 894083 1.00000 1.00000 0.00000 0.00000 X X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED Part Iii Annual meeting Part iii line 4a Support of the Foundation for Thymic Cancer Research and joint program services Part Iii line 4b database collection, management, and analysis Part III, Line 4d With 147 active members from 21 countries, ITMIG continues to be the leading scientific organization dedicated to thymic malignancies. ITMIG Committees are the core of our society, and beyond our Annual Meeting, are working all along the year on research projects, patients- and physicians-oriented initiatives, and developing the infrastructures for novel initiatives. Participation is open to all ITMIG members, and we need your input, engagement, and leadership in all these activities. The ITMIG prospective database is being transferred to a REDCap format, which allows better self-updating, higher compatibility with other systems, and more opportunities for developing a central platform for projects. It is also compliant with recent regulation on data usage. Thanks to the TYME network, the infrastructure database is now ready. A comprehensive review of data elements to be collected was done, and new fields have been added, especially to prepare the next version of the TNM classification. In 2022 and 2023, we organized nine clinical-radiological-pathological meetings, i.e. multidisciplinary Tumor Boards, at which patient cases are presented. In order to improve the organization of the meetings, we appointed a Tumor Board chair in 2023, with Annemarie Shepherd assuming this position. Two cases presented at the Tumor Board were subsequently published in Mediastinum. ITMIG declared May as Thymic Malignancy Awareness Month (TMAM). To mark the occasion, several webinars for physicians and patients were held in May. Some were prepared in cooperation with other scientific societies (the European Society of Pathology, the Society of Thoracic Radiology, the American Radium Society) or patient support groups (ThymicUK, TUTOR). Majority of webinars were recorded and are now available on ITMIG YouTube channel. In addition, a patient information brochure available in 11 languages, numerous informational posts on Facebook and interviews with prominent ITMIG members were prepared and published on the Mediastinum website. The time and effort spent preparing We recently initiated a project on the pathologic and radiologic tumor response to neoadjuvant therapy in thymic carcinomas, thymomas, and thymic neuroendocrine neoplasms. Aims of the study are to assess radiologic and pathologic response to neoadjuvant therapy and to correlate response with outcome. As we are still in the early stages of the project, anyone is welcome to join the project. A workshop of participating pathologists is planned in the morning of October 7th 2024, the day after the Annual ITMIG meeting, at NYU organized by Dr. Andre Moreira. The working group is assembling a multidisciplinary survey on questions relevant to various subspecialties, specifically focusing on questions towards cooperation between subspecialties and on current state of management of patients with thymoma and thymic carcinoma, aspects that were not included in the survey published by ITMIG and led by Dr. Annemarie Shepard in 2017, PMID: 27876674. We are currently working on a primary mediastinal germ cell tumor (PMGCT) project. Because of the paucity of PMGCT studies are in general small and information is relatively sparse. Furthermore, there is currently no agreed upon staging for PMGCT. We study the morphologic and imaging features of PMGCT and will correlate those with outcome. In addition, we will correlate demographic features and surgical treatment with outcome of patients and collect molecular data. Ultimately, we would like to establish a staging system for PMGCT. Currently, we review the morphologic and immunophenotypic features of PMGCT by web meetings. October 4-6, 2023, the Annual Meeting of ITMIG (13th) was held in New York. After three years of virtual meetings, we finally met in person! The conference was well attended, with 167 participants from 16 countries. The conference program included educational and scientific sessions, Radiation Oncology Workshop, patient sessions and also Oral Abstract and Poster Sessions. A total of 45 abstracts were presented. The winner for the best abstract was Dr. Sana Raoof, who presented the results of the study titled Outcomes and Toxicities of Definitive Radiation Therapy for Unresected Thymic Malignancies. The 2024 Annual Meeting was held in Yokohama, Japan. The 2025 annual meeting will be held in Milan, Italy. Part VI, Line 19 Financial and government documents are available in the office Extension filed. Preparer was ill and recovering from surgery, took much longer than anticipated to collect required information.